Company: LGN
Filing Date: 2025-08-15
Form Type: S-1
Source: 0001193125-25-181698
Chunk: 98

Company: Legence Corp.
Filing Date: 2025-08-15
Form: S-1
Chunk 98
---
 or persons acting on our behalf may issue. Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this prospectus. 62

USE OF PROCEEDS

We expect to receive approximately $ million (or approximately $ million if the
underwriters exercise in full their option to purchase additional shares of Class A Common Stock) of net proceeds from the sale of the Class A Common Stock offered by us based upon the assumed public offering price of
$ per share of Class A Common Stock (the midpoint of the price range set forth on the cover page of this prospectus), after deducting underwriting discounts and commissions and estimated offering expenses payable by
us.

We intend to contribute all of the net proceeds from this offering (not including the exercise of the underwriters’ option to
purchase additional shares) to Legence Holdings in exchange for LGN Units. Legence Holdings intends to use such net proceeds from this offering for the repayment of outstanding borrowings under our Term Loan Credit Facility and the remaining
proceeds for general corporate purposes.

We intend to contribute the net proceeds received from the sale of any additional shares by us
to Legence Holdings in exchange for additional LGN Units being issued to Legence Sub, and Legence Holdings will use such net proceeds to purchase LGN Units, together with an equal number of shares of Class B Common Stock, from Legence Parent at
a purchase price per LGN Unit and share of Class B Common Stock equal to the public offering price per share of Class A Common Stock in this offering, net of underwriting discounts and commissions.

We will not receive any proceeds from the sale of additional shares of Class A Common Stock by the selling stockholder. We will, however, bear
the costs associated with the sale of additional shares of Class A Common Stock by the selling stockholder, other than underwriting discounts and commissions. For more information, see “Principal and Selling Stockholders” and
“Underwriting (Conflicts of Interest).”

As of June 30, 2025 and December 31, 2024, we had an outstanding principal
balance of approximately $1,582.1 million and $1,590.4 million, respectively, under the Term Loan Credit Facility. The Term Loan Credit Facility matures on December 16, 2028. Legence Holdings can elect for borrowings of term loans
(including